MedPath

Cefotaxime

Generic Name
Cefotaxime
Brand Names
Claforan
Drug Type
Small Molecule
Chemical Formula
C16H17N5O7S2
CAS Number
63527-52-6
Unique Ingredient Identifier
N2GI8B1GK7

Overview

Cefotaxime is a third-generation cephalosporin antibiotic. Like other third-generation cephalosporins, it has broad spectrum activity against Gram positive and Gram negative bacteria. In most cases, it is considered to be equivalent to ceftriaxone in terms of safety and efficacy. Cefotaxime sodium is marketed under various trade names including Claforan (Sanofi-Aventis).

Background

Cefotaxime is a third-generation cephalosporin antibiotic. Like other third-generation cephalosporins, it has broad spectrum activity against Gram positive and Gram negative bacteria. In most cases, it is considered to be equivalent to ceftriaxone in terms of safety and efficacy. Cefotaxime sodium is marketed under various trade names including Claforan (Sanofi-Aventis).

Indication

Used to treat gonorrhoea, meningitis, and severe infections including infections of the kidney (pyelonephritis) and urinary system. Also used before an operation to prevent infection after surgery.

Associated Conditions

  • Bone and Joint Infections caused by susceptible Bacterial Infections
  • Central Nervous System Infections caused by susceptible Bacterial Infections
  • Genitourinary tract infection caused by susceptible Bacterial Infections
  • Gynaecological infection caused by susceptible bacteria
  • Intraabdominal Infections caused by susceptible Bacterial Infections
  • Lower Respiratory Tract Infection (LRTI) caused by susceptible bacteria
  • Postoperative Wound Infection
  • Septicemia caused by susceptible Bacterial Infections
  • Skin and skin-structure infections caused by susceptible bacteria

FDA Approved Products

Cefotaxime
Manufacturer:SteriMax Inc.
Route:INTRAMUSCULAR, INTRAVENOUS
Strength:1 g in 1 1
Approved: 2019/08/01
NDC:21586-011
Cefotaxime
Manufacturer:SteriMax Inc.
Route:INTRAMUSCULAR, INTRAVENOUS
Strength:2 g in 1 1
Approved: 2019/08/01
NDC:21586-012
Cefotaxime
Manufacturer:Hikma Pharmaceuticals USA Inc.
Route:INTRAMUSCULAR, INTRAVENOUS
Strength:2 g in 1 1
Approved: 2021/05/25
NDC:0143-9933
Cefotaxime
Manufacturer:Hikma Pharmaceuticals USA Inc.
Route:INTRAMUSCULAR, INTRAVENOUS
Strength:1 g in 1 1
Approved: 2021/05/25
NDC:0143-9931
Cefotaxime
Manufacturer:West-Ward Pharmaceuticals Corp
Route:INTRAVENOUS
Strength:10 g in 1 1
Approved: 2018/09/17
NDC:0143-9935

Singapore Approved Products

CYTAXIN POWDER FOR SOLUTION FOR INJECTION 0.5G/VIAL
Manufacturer:TENAMYD PHARMACEUTICAL CORPORATION
Form:INJECTION, POWDER, FOR SOLUTION
Strength:0.5g/vial
Online:Yes
Approved: 2021/11/10
Approval:SIN16367P
CYTAXIN POWDER FOR SOLUTION FOR INJECTION 1G/VIAL
Manufacturer:TENAMYD PHARMACEUTICAL CORPORATION
Form:INJECTION, POWDER, FOR SOLUTION
Strength:1g/vial
Online:Yes
Approved: 2021/11/10
Approval:SIN16368P

Drug Development Updates

Stay informed with timely notifications on clinical trials and research advancements.

© Copyright 2025. All Rights Reserved by MedPath